Arginin-Vasopressin im septischen und vasodilatatorischen Schock

Zusammenfassung

Die derzeitige Therapie des septischen/vasodilatorischen Kreislaufversagens umfasst die Volumentherapie sowie die Infusion inotroper und vasoaktiver Substanzen. Noradrenalin ist dabei das Vasokonstringens der ersten Wahl und führt bei den meisten Patienten zu einer Stabilisierung des Schockzustandes. Dennoch stellt das irreversible Kreislaufversagen, bei dem die konventionelle hämodynamische Therapie versagt, die häufigste Todesursachen von Patienten mit schwerer Sepsis und septischem Schock dar. Bei solchen fortgeschrittenen, Katecholamin-refraktären Schockzuständen führte Arginin-Vasopressin (AVP) wiederholt zu einem Anstieg des mittleren arteriellen Blutdrucks, einer Reduktion toxisch-hoher Noradrenalin Dosen sowie zu weiteren positiven hämodynamischen, endokrinologischen und renalen Veränderungen. Obwohl AVP in früheren klinischen Untersuchungen und in einzelnen Tieruntersuchungen negative inotrope Effekte hatte, führt eine kontinuierliche niedrig-dosierte AVP-Infusion bei Patienten mit fortgeschrittenem septischen/vasodilatorischen Schock nur bei hyperdynamen Kreislaufverhältnissen zu einem Abfall des Cardiac Index. Negative Auswirkungen auf die Darmzirkulation und die systemische Mikrozirkulation können nicht ausgeschlossen werden, wurden allerdings in der klinischen Praxis noch nicht an einem grossen Kollektiv in einer prospektiven Studie bestätigt. Nebenwirkungen einer zusätzlichen AVP Therapie im septischen/vasodilatorischen Schock sind ein Anstieg des Gesamtbilirubins, sowie ein Abfall der Thrombozytenzahlen. Ein vorübergehender Anstieg der hepatischen Transaminasen unter AVP Therapie ist wahrscheinlich meist in Zusammenhang mit vorausgehenden hypotensiven Episoden zu bringen. Wichtige Punkte, die bei der Anwendung von AVP als "rescue vasopressor" im septischen/vasodilatorischen Schock beachtet werden müssen, sind: 1) Infusion von AVP nur in fortgeschrittenen Schockzuständen, bei denen eine konventionelle Therapie nicht zur Kreislaufstabilisierung ausreicht (z.B. Noradrenalin-Dosierungen >0,5-0,6 μg/kg/min), 2) Sicherstellung einer Normovolämie, 3) Infusion von AVP ausschliesslich in Kombination mit Noradrenalin, 4) strikte Vermeidung von Bolusinjektionen sowie Steigerungen der kontinuierlichen Dosierungen >4 IU/h. Die Auswirkungen einer zusätzlichen AVP Therapie auf die Mortalität im fortgeschrittenen septischen/vasodilatorischen Schock wird derzeit in einer grossen Multicenter Studie in Nordamerika und Australien untersucht.

Abstract

Current therapy of septic/vasodilatory cardiovascular failure includes volume resuscitation and infusion of inotropic and vasopressor agents. Norepinephrine is the first-line vasoconstrictor, and can stabilize hemodynamic variables in most patients. Nontheless, irreversible cardiovascular failure which is resistant to conventional hemodynamic therapies still is the main cause of death in patients with severe sepsis and septic shock. In such advanced, catecholamine-resistant shock states, arginine-vasopressin (AVP) has repeatedly caused an increase in mean arterial blood pressure, a decrease in toxic norepinephrine-dosages, as well as further beneficial hemodynamic, endocrinologic and renal effects. Although AVP exerted negative inotropic effects in previous clinical trials and in selected animal experiments, a continuous low-dose AVP infusion during advanced septic/vasodilatory shock caused a decrease in cardiac index only in patients with a hyperdynamic circulation. Adverse effects on gastrointestinal circulation and the systemic microcirculation can not be excluded, but have not yet been confirmed in clinical prospective trials. Negative side effects of a supplementary AVP therapy are an increase in total bilirubin concentrations, and a decrease in platelet count. A transient increase in hepatic transaminases during AVP infusion is most likely related to preceding hypotensive episodes. Important points which must be considered when using AVP as a "rescue vasopressor" in septic/vasodilatory shock states are: 1) AVP infusion only in advanced shock states that can not be adequately reversed by conventional hemodynamic therapy (e.g. norepinephrine >0,5-0,6 μg/kg/min), 2) presence of normovolemia, 3) AVP infusion only in combination with norepinephrine, 4) strict avoidance of bolus injections and dosages >4 IU/h. Effects of a supplementary AVP infusion in advanced vasodilatory shock on survival are currently examined in a large, prospective multicenter trial in North America and Australia.

arginin vasopressin - septischer schock - vasodilatorischer schock - noradrenalin - nebenwirkungen

arginine vasopressin - septic shock - vasodilatory shock - norepinephrine - side effects

Literaturverzeichnis

• 1 Dellinger RP, Carlet JM, Masur H. et al. . Surviving Sepsis guidelines for management of severe sepsis and septic shock.  Crit Care Med. 2004;  32 858-873
• 2 Beale RJ, Hollenberg SM, Vincent JL, Parrillo JE. Vasopressor and inotropic support in septic shock: an evidence-based review.  Crit Care Med. 2004;  32 455-465
• 3 Martin C, Papazian L, Perrin G, Saux P, Gouin F. Norepinephrine or dopamine for the treatment of hyperdynamic septic shock?.  Chest. 1993;  103 1826-1831
• 4 Giantomasso D Di, May CN, Bellomo R. Norepinephrine and vital organ blood flow during experimental hyperdynamic sepsis.  Intensive Care Med. 2003;  29 1774-1781
• 5 Morimatsu H, Singh K, Uchino S, Bellomo R, Hart G. Early and exclusive use of norepinephrine in septic shock.  Resuscitation. 2004;  62 249-254
• 6 Parrillo JE. Pathogenetic mechanisms of septic shock.  N Engl J Med. 1993;  328 1471-1477
• 7 Landry DW, Oliver JA. The pathogenesis of vasodilatory shock.  N Engl J Med. 2001;  345 588-595
• 8 Schwertz H, Müller-Werdan U, Prondzinsky R, Werdan K, Buerke M.  Catecholamine therapy in cardiogenic shock: helpful, useless of dangerous?.  Dtsch Med Wochenschr. 2004;  129 1925-1930
• 9 Dünser M, Wenzel V, Mayr AJ, Hasibeder WR. Arginine vasopressin in vasodilatory shock: a new therapy approach?.  Anaesthesist. 2002;  51 650-659
• 10 Luckner G, Dünser MW, Jochberger S. et al. .Arginine vasopressin in 316 patients with advanced vasodilatory shock. Crit Care Med 2005
• 11 Landry DW, Levin HR, Gallant EM. et al. . Vasopressin pressor hypersensitivity in vasodilatory septic shock.  Crit Care Med. 1997;  25 1279-1282
• 12 Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle 3rd WA. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock.  Crit Care Med. 2001;  29 487-493
• 13 Morales DL, Gregg D, Helman DN. et al. . Arginine vasopressin in the treatment of 50 patients with postcardiotomy vasodilatory shock.  Ann Thorac Surg. 2000;  69 102-106
• 14 Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock.  Anesthesiology. 2002;  96 576-582
• 15 Holmes CL, Walley KR, Chittock DR, Lehman T, Russel JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series.  Intensive Care Med. 2001;  27 1416-1421
• 16 Dünser MW, Mayr AJ, Ulmer H. et al. . Arginine vasopressin in advanced vasodilatory shock: a prospective, randomized, controlled trial.  Circulation. 2003;  107 2313-2319
• 17 Dünser MW, Mayr AJ, Ulmer H. et al. . The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis.  Anesth Analg. 2001;  93 7-13
• 18 Dünser MW, Hasibeder WR, Wenzel V. et al. . Endocrinologic response to vasopressin infusion in advanced vasodilatory shock.  Crit Care Med. 2004;  32 1266-1271
• 19 Shelly MP, Greatorex R, Calne RY. et al. . The physiological effects of vasopressin when used to control intraabdominal bleeding.  Intensive Care Med. 1988;  14 526-531
• 20 Scharte M, Meyer J, Aken H Van, Bone HG. Hemodynamic effects of terlipressin (a synthetic analog of vasopressin) in healthy and endotoxemic sheep.  Crit Care Med. 2001;  29 1756-1760
• 21 Westphal M, Stubbe H, Sielenkämper AW. et al. . Terlipressin dose response in healthy and endotoxemic sheep: impact on cardiopulmonary performance and global oxygen transport.  Intensive Care Med. 2003;  29 301-308
• 22 Malay MB, Ashton JL, Dahl K. et al. . Heterogenity of the vasoconstrictor effect of vasopressin in septic shock.  Crit Care Med. 2004;  32 1327-1331
• 23 Albert M, Losser MR, Hayon D, Faivre V, Payen D. Systemic and renal macro- and microcirculatory responses to arginine vasopressin in endotoxic rabbits.  Crit Care Med. 2004;  32 1891-1898
• 24 Fujisawa S, Iijima T. On the inotropic actions of arginine vasopressin in ventricular muslce of the guinea pig heart.  Jpn J Pharmacol. 1999;  81 309-312
• 25 Okamura T, Ayajiki K, Fujioka H, Toda N. Mechanisms underlying arginine vasopressin-induced relaxation in monkey isolated coronary arteries.  J Hypertens. 1999;  17 673-678
• 26 Mayr VD, Wenzel V, Muller T. et al. . Effects of vasopressin on left anterior descending coronary artery blood flow during extremely low cardiac output.  Resuscitation. 2004;  62 229-235
• 27 Dünser MW, Mayr AJ, Stallinger A, et al.  Cardiac performance during vasopressin infusion in postcardiotomy shock.  Intensive Care Med. 2002;  28 746-751
• 28 Hjalmarson A. Significance of reduction in heart rate in cardiovascular disease.  Clin Cardiol. 1998;  21 3-7
• 29 Meier-Hellmann A. Arginin-Vasopressin im vasodilatorischen Schock - gesicherte Therapieoption oder ultima ratio?.  Anaesthesist. 2002;  51 659-660
• 30 Ertmer C, Sielenkämper AW, Aken H van, Bone HG, Westphal M. Vasopressin and terlipressin in sepsis and systemic inflammatory response syndrome. Effects on microcirculation, oxygen transport, metabolism and organ function.  Anaesthesist. 2005;  54 346-356
• 31 Martikainien TJ, Tenhunen JJ, Uusaro A, Ruokonen E. The effects of vasopressin on systemic and splanchnic hemodynamics and metabolism in endotoxin shock.  Anesth Analg. 2003;  97 1756-1763
• 32 Westphal M, Freise H, Kehrel BE. et al. . Arginine vasopressin compromises gut mucosal microcirculation in septic rats.  Crit Care Med. 2004;  31 194-200
• 33 Sun Q, Dimopoulos G, Nguyen DN. et al. . Low dose vasopressin in the treatment of septic shock in sheep.  Am J Respir Crit Care Med. 2003;  168 481-486
• 34 Asfar P, Pierrot M, Veal N. et al. . Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats.  Crit Care Med. 2003;  31 215-220
• 35 Asfar P, Hauser B, Ivanyi Z. et al. . Low-dose terlipressin during long-term hyperdynamic porcine endotoxemia: effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism.  Crit Care Med. 2005;  33 373-380
• 36 Venkateswaran RV, Charman SC, Goddard M, Large SR. Lethal mesenteric ischaemia after cardiopulmonary bypass: a common complication?.  Eur J Cardiothorac Surg. 2002;  22 538
• 37 Luckner G, Jochberger S, Mayr VD. et al. .Vasopressin as adjunct vasopressor for vasodilatory shock due to non-occlusive mesenteric ischemia. Anaesthesist 2005
• 38 Dubois MJ, De D Backer, Creteur J, Anane S, Vincent JL. Effect of vasopressin on sublingual microcirculation in a patient with distributive shock.  Intensive Care Med. 2003;  29 1020-1023
• 39 Dünser MW, Mayr AJ, Tür A. et al. . Ischemic skin lesions as a complication of continuous vasopressin infusion in catecholamine-resistant vasodilatory shock: incidence and risk factors.  Crit Care Med. 2003;  31 1394-1398
• 40 Hamada Y, Karjalainen A, Setchell BA. et al. . Concomitant stimulation by vasopressin of biliary and perfusate calcium fluxes in the perfused rat liver.  Biochem J. 1992;  281 387-392
• 41 Ballatori N, Truong AT. Cholestasis, altered junctional permeability, and inverse changes in sinusoidal and biliary glutathione release by vasopressin and epinephrine.  Mol Pharmacol. 1990;  38 64-71
• 42 Dünser MW, Fries DR, Schobersberger W. et al. . Does arginine vasopressin influence the coagulation system in advanced vasodilatory shock with severe multiorgan dysfunction syndrome?.  Anesth Analg. 2004;  99 201-206
• 43 Klinzing S, Simon M, Reinhart K, Bredle DL, Meier-Hellmann A. High-dose vasopressin is not superior to norepinephrine in septic shock.  Crit Care Med. 2003;  31 2646-2650
• 44 Russell JA, Cooper DJ, Walley KR. et al. . Vasopressin and Septic Shock Trial (VASST): baseline characteristics and organ dysfunction in vasopressor dependent patients with septic shock.  Am J Respir Crit Care Med. 2003;  167 A548
• 45 Mols G, Loop T, Hermle G. et al. . Ten years experience with extracorporeal membrane oxygenation.  Anaesthesiol Intensivmed Notfallmed Schmerzther. 2001;  36 4-14
• 46 Mair P, Hoermann C, Moertl M, Bonatti J, Falbesoner C, Balogh D. Percutaneous venoarterial extracorporeal membrane oxygenation for emergency mechanical circulatory support.  Resuscitation. 1996;  33 29-34
• 47 Dunser MW, Mayr AJ, Ulmer H, Ritsch N, Knotzer H, Pajk W, Luckner G, Mutz NJ, Hasibeder WR. The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: a retrospective analysis.  Anesth Analg. 2001;  93 7-13
• 48 Holmes CL, Walley KR, Chittock DR, Lehman T, Russell JA. The effects of vasopressin on hemodynamics and renal function in severe septic shock: a case series.  Intensive Care Med. 2001;  27 1416-1421
• 49 O'Brien A, Clapp L, Singer M. Terlipressin for norepinephrine-resistant septic shock.  Lancet. 2002;  359 1209-1210
• 50 Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock.  Anesthesiology. 2002;  96 576-582
• 51 Tsuneyoshi I, Yamada H, Kakihana Y, Nakamura M, Nakano Y, Boyle III WA. Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock.  Crit Care Med. 2001;  29 487-493
• 52 Reinhart K, Brunkhorst FM, Bone HG, Gerlach H, Grundling M, Kreymann G, Kujath P, Marggraf G, Mayer K, Meier-Hellmann A, Peckelsen C, Putensen C, Quintel M, Ragaller M, Rossaint R, Stuber F, Weiler N, Welte T, Werdan K. Diagnosis and Therapy of Sepsis : Guidelines of the German Sepsis Society Inc. and the German Interdisciplinary Society for Intensive and Emergency Medicine.  Internist (Berl). 2006;  47 356-373
• 53 Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis.  JAMA. 1994;  272 1354-1357
• 54 Sakr Y, Reinhart K, Vincent JL, Sprung CL, Moreno R, Ranieri VM, De BD, Payen D. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill Patients (SOAP) Study.  Crit Care Med. 2006;  34 589-597
• 55 Bellomo R, Giantomasso DD. Noradrenaline and the kidney: friends or foes?.  Crit Care. 2001;  5 294-298
• 56 Theilmeier G, Booke M. Norepinephrine in septic patients-friend or foe?.  J Clin Anesth. 2003;  15 154-158
• 57 Klinzing S, Simon M, Reinhart K, Bredle DL, Meier-Hellmann A. High-dose vasopressin is not superior to norepinephrine in septic shock.  Crit Care Med. 2003;  31 2646-2650
• 58 Martikainen TJ, Tenhunen JJ, Uusaro A, Ruokonen E. The effects of vasopressin on systemic and splanchnic hemodynamics and metabolism in endotoxin shock.  Anesth Analg. 2003;  97 1756-1763
• 59 Varga C, Pavo I, Lamarque D, Szepes Z, Kiss J, Karacsony G, Laszlo FA, Laszlo F. Endogenous vasopressin increases acute endotoxin shock-provoked gastrointestinal mucosal injury in the rat.  Eur J Pharmacol. 1998;  352 257-261
• 60 Martikainen TJ, Tenhunen JJ, Uusaro A, Ruokonen E. The effects of vasopressin on systemic and splanchnic hemodynamics and metabolism in endotoxin shock.  Anesth Analg. 2003;  97 1756-1763
• 61 Landry DW, Levin HR, Gallant EM, Ashton Jr. RC, Seo S, D'Alessandro D, Oz MC, Oliver JA. Vasopressin deficiency contributes to the vasodilation of septic shock.  Circulation. 1997;  95 1122-1125
• 62 Haren FM van, Rozendaal FW, Hoeven JG van der. The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock.  Chest. 2003;  124 2256-2260